OtologicPharmaceutics
Therapeutic Solutions for Hearing Health
Latest Press & Media
TINNITUS TOGETHER
Beginning January 15, 2024, our collaborators at the Hough Ear Institute (HEI) will be offering Tinnitus Together, the first peer-to-peer tinnitus support group in the State of Oklahoma. This no-cost support group will be led by a licensed professional counselor,...
![2](https://otologicpharma.com/wp-content/uploads/2013/12/2.jpg)
Our mission
Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.
![AI-Illustrations_05](https://otologicpharma.com/wp-content/uploads/2021/12/AI-Illustrations_05.png)
Our mission is to treat hearing loss.
Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.
OPI’s program NHPN-1010, an oral medication to treat acute hearing loss, has successfully completed a Phase I clinical trial. Initial research focuses on NHPN-1010 as a treatment for Noise Induced Hearing Loss. OPI’s program OPI-001, an innovative treatment for acute and chronic hearing loss through the regeneration of sensory hair cells, has been awarded a Congressionally Directed Medical Research Programs grant from the Department of Defense to fund further preclinical research and development.
Contact us
Call Us
Email Us
ehamm@ascendbioventures.com
Our Location
840 Research Parkway
Suite 250
Oklahoma City, OK 73104